Using prostate cancer as a focus, where acquired resistance to docetaxel (DTX) signifies a point of no return for patients, we demonstrate that DTX acts by a paracrine mechanism to promote tumor cell survival and outgrowth via a HMGB1/TLR4-RAGE/sCLU pathway. Here, HMGB1 is linked to neoplasm.